Ankylosing Spondylitis Pipeline Shows Robust Growth with 20+ Therapies in Development
Key Insights
DelveInsight (search)'s 2025 pipeline analysis reveals over 20 companies are actively developing 20+ novel therapies for ankylosing spondylitis (search) treatment across various clinical phases.
UCB (search)'s BIMZELX demonstrated long-term inflammation control in three-year Phase 3 data, while becoming the first dual IL-17A/IL-17F (search) inhibitor approved in Canada for ankylosing spondylitis (search).
Multiple promising candidates including sonelokimab, NEU-111, and secukinumab are advancing through clinical trials, targeting different pathways to address unmet medical needs.
The ankylosing spondylitis (search) therapeutic landscape is experiencing unprecedented growth, with DelveInsight (search)'s latest pipeline analysis revealing more than 20 companies actively developing over 20 novel treatment therapies for this chronic inflammatory condition. The comprehensive assessment spans products from pre-clinical development through marketed phases, highlighting significant advances in addressing the substantial unmet medical needs for patients with this debilitating autoimmune disease.
Recent Clinical Milestones Drive Market Momentum
UCB (search)'s BIMZELX (bimekizumab-bkzx) has emerged as a standout therapy, with the company releasing new three-year data from Phase 3 clinical trials and open-label extension studies in June 2025. The dual inhibitor targeting IL-17A and IL-17F (search) demonstrated long-term inflammation control and robust efficacy in managing both psoriatic arthritis (search) and axial spondyloarthritis (search), which includes ankylosing spondylitis (search). These chronic inflammatory conditions significantly affect patients' physical and emotional health, making the sustained efficacy particularly noteworthy.
The regulatory landscape has also shifted favorably for BIMZELX, as UCB (search) Canada successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance in February 2025. Following positive reimbursement recommendations from Canada's Drug Agency and Quebec's Institut National d'Excellence en Santé et en Services Sociaux, BIMZELX became the first and only biologic approved in Canada that inhibits both IL-17A and IL-17F (search). Health Canada had previously authorized its use for active psoriatic arthritis (search) on February 23, 2024, and for axial spondyloarthritis (search), including ankylosing spondylitis (search), on March 11, 2024.
Diverse Pipeline Approaches Target Multiple Pathways
The current pipeline showcases remarkable diversity in therapeutic approaches and mechanisms of action. Key emerging therapies include KIN-1901 from Kinevant Sciences (search), sonelokimab from MoonLake Immunotherapeutics, QX 002N from Qyuns Therapeutics (search), SHR-1314 from Suzhou Zelgen Biopharmaceuticals (search), SHR0302 from Jiangsu HengRui Medicine, jaktinib from Suzhou Zelgen Biopharmaceuticals, and apremilast from Amgen.
Sonelokimab, a nanobody developed by MoonLake Immunotherapeutics, is currently undergoing screening for a Phase 2 clinical trial in Germany. The open-label study, named S-OLARIS, aims to assess the efficacy of sonelokimab in reducing inflammation in the spine and sacroiliac joints. The trial plans to enroll approximately 25 patients, all receiving a 60 mg dose via subcutaneous injection.
Novel Mechanisms Enter Clinical Testing
Neuron23 (search)'s NEU-111 represents an innovative approach to ankylosing spondylitis (search) treatment, with the company announcing the commencement of dosing in a Phase 1 clinical trial in December 2024. NEU-111 is a highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2 (search)), a member of the JAK protein family involved in pathological immune signaling. With best-in-class potential, NEU-111 reduces signaling through multiple cytokine receptors, including those for interleukin-12, IL-23 (search), and interferon. TYK2 is associated with various immune-mediated inflammatory diseases, including ankylosing spondylitis.
Long-term Safety and Efficacy Data Emerge
The SERENA study provided valuable long-term insights in April 2025, with a three-year interim analysis offering data on the safety, effectiveness, and treatment retention of secukinumab in managing psoriatic arthritis (search) and ankylosing spondylitis (search). This completed multinational, longitudinal, observational study evaluated patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, or active ankylosing spondylitis who had been on commercially available secukinumab for at least 16 weeks prior to enrollment.
Comprehensive Pipeline Spans Multiple Development Phases
DelveInsight (search)'s analysis reveals that the ankylosing spondylitis (search) pipeline encompasses products across all development stages, including late-stage Phase III products, mid-stage Phase II candidates, early-stage Phase I therapies, and pre-clinical discovery stage candidates. The therapeutic approaches span multiple molecule types, including recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy.
Route of administration varies significantly across the pipeline, with products categorized as oral, intravenous, subcutaneous, intramuscular, and topical formulations. This diversity provides potential options for different patient preferences and clinical scenarios.
Market Dynamics Present Opportunities and Challenges
The ankylosing spondylitis (search) market is being driven by rising disease prevalence and increased drug development activity. However, significant barriers remain, including lack of early diagnosis, minimal patient participation in physical activity, high treatment costs, and lack of caregiver support.
Key companies actively developing ankylosing spondylitis (search) therapies include established pharmaceutical giants such as Pfizer, UCB (search) Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, and Gilead Sciences, alongside emerging biotechnology companies like Kinevant Sciences (search), MoonLake Immunotherapeutics, and Neuron23 (search).
The comprehensive pipeline analysis indicates that ankylosing spondylitis (search), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is receiving unprecedented attention from the pharmaceutical industry. The condition, which causes pain, stiffness, and reduced mobility and can lead to spinal vertebrae fusion over time, is an autoimmune condition often linked to the HLA-B27 (search) gene and typically begins in early adulthood.